Last quarter (Q ), Panacos Pharmaceuticals's total revenue was $24.00K, a decrease of -20.00% from the same quarter last year. In Q, Panacos Pharmaceuticals's net income was $-8.15M. See Panacos Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 07	Dec 06	Dec 05	Dec 04	Dec 03
Total Revenue	$ 99.00K	$ 180.00K	$ 284.00K	$ 1.05M	$ 1.68M	$ 715.77K
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 34.32M	$ 39.20M	$ 41.98M	$ 41.62M	$ 19.75M	$ 22.84M
Operating Income	$ -34.22M	$ -39.02M	$ -41.70M	$ -40.57M	$ -18.06M	$ -22.13M
Net Non Operating Interest Income Expense	-	-	-	-	-	-
Other Income Expense	$ -8.00K	$ -1.29M	$ -6.00K	$ -33.20M	-	-
Pretax Income	-	-	-	-	-	-
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -35.76M	$ -37.46M	$ -38.11M	$ -59.08M	$ -18.16M	$ -22.35M
Basic EPS	$ -0.66	$ -0.70	$ -0.75	$ -1.72	$ -3.50	$ -6.70
Diluted EPS	$ -0.66	$ -0.70	$ -0.75	$ -1.72	$ -3.50	$ -6.70
Basic Average Shares	$ 214.46M	$ 53.15M	$ 50.52M	$ 34.42M	$ 5.25M	$ 3.34M
Diluted Average Shares	$ 214.46M	$ 53.15M	$ 52.88M	$ 49.22M	$ 5.25M	$ 3.34M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 34.32M	$ 39.20M	$ 41.98M	$ 41.62M	$ 19.75M	$ 22.84M
Net Income From Continuing And Discontinued Operation	$ -35.76M	$ -37.46M	$ -38.11M	$ -59.08M	$ -18.16M	$ -22.35M
Normalized Income	$ -35.75M	$ -36.17M	$ -38.10M	$ -25.88M	$ -18.16M	$ -22.35M
Interest Expense	-	-	-	-	-	-
EBIT	$ -34.22M	$ -39.02M	$ -41.70M	$ -40.57M	$ -18.06M	$ -22.13M
EBITDA	$ -33.00M	$ -38.23M	$ -40.94M	$ -39.94M	$ -17.09M	$ -21.07M

Currency in USD

Panacos Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing